

share
Temarotene CAS NO 89410-65-1
Unit Price:
CAS No.:89410-65-1
Grade:Pharmacy Grade
Content:99.9%
Brand:Customizable
Packaging:Customizable
Description
Temarotene is a synthetic retinoid compound with significant pharmacological activity. This active pharmaceutical ingredient (API) is valued for its targeted therapeutic effects in dermatological and oncological research. It is primarily utilized by pharmaceutical manufacturers and research institutions engaged in the development of novel treatments. Our supply ensures high purity and consistent quality for critical R&D and production needs.
Application
- Pharmaceutical Active Ingredient (API): Core component in the formulation of prescription dermatological medications.
- Dermatological Research: Investigation into treatments for severe acne, psoriasis, and other keratinization disorders.
- Oncology Research: Studies exploring its potential in chemoprevention and differentiation therapy for certain cancers.
- Preclinical & Clinical Development: Sourcing for toxicity studies, pharmacokinetic profiling, and clinical trial material.
- Reference Standard: Used as an analytical standard in quality control laboratories for method development and validation.
- Cosmeceutical R&D: Exploration in advanced anti-aging and skin-repair formulations at the research stage.
Basic Information
| Product Name | Temarotene |
| CAS No. | 89410-65-1 |
| Molecular Formula | C23H28O2 |
| Molecular Weight | 336.47 g/mol |
| Synonyms | 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl]benzoic Acid; Ro 15-0778; Arotinoid Ethylester; Temarotène; Temaroteno |
| EINECS | Contact for details |
Quality Control
Our Temarotene is manufactured under strict quality management systems. Each batch is subjected to comprehensive analytical testing including HPLC for purity, residual solvent analysis, and identification by spectroscopic methods. We provide full traceability and Certificates of Analysis (COA) are available for all shipments, ensuring compliance with cGMP guidelines for pharmaceutical intermediates.
Storage
Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept in a dry environment to maintain stability and purity.
Specification
| Item | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification (IR) | Conforms to reference spectrum |
| Identification (HPLC) | Retention time matches reference standard |
| Assay (HPLC) | ≥ 98.5% |
| Related Substances (HPLC) | Total impurities ≤ 1.5% Any single impurity ≤ 0.5% |
| Residual Solvents (GC) | Complies with ICH Q3C guidelines |
| Loss on Drying | ≤ 0.5% |
| Heavy Metals | ≤ 20 ppm |
Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.
Hot Related Products


Crotamiton CAS NO 483-63-6


Ichthosulfonate CAS NO 8029-68-3


Trifarotene CAS NO 895542-09-3


Acitretin CAS NO 55079-83-9


Minoxidil CAS NO 38304-91-5


Isotretinoin CAS NO 4759-48-2


Biotinoyl Tripeptide-1 CAS NO 299157-54-3


Retinoic Acid CAS NO 302-79-4


(Z)-Crotamiton CAS NO 124236-30-2


Bismuth Subgallate CAS NO 99-26-3


Monobenzone CAS NO 103-16-2


Merbromin CAS NO 129-16-8


Anthralin CAS NO 1143-38-0


Calcium Undecylenate CAS NO 1322-14-1


Copperundecylenate CAS NO 1322-15-2


Hirudoid Gel CAS NO 11097-84-0


Calamine CAS NO 12196-21-3


Chlorophyllypt CAS NO 12750-97-9


(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,2,6-Trimethyl-7-Oxabicyclo[4.1.0]Hept- 1-Yl)-2,4,6,8-Nonatetraenoic Acid CAS NO 13100-69-1


Zinc Salicylate CAS NO 16283-36-6
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.






